Table 2.
Summary of surgical outcomes in the Chinese subpopulation
| Nivolumab plus chemotherapy (n = 44)a | Chemotherapy (n = 53) | |
|---|---|---|
| Completed definitive surgery, n (%) | 36 (82) | 41 (77) |
| Cancelled definitive surgery, n (%) | 7 (16) | 12 (23) |
| Disease progressionb | 4 (57) | 6 (50) |
| Otherb | 3 (43) | 6 (50) |
| Delayed definitive surgery, n (%) | 3 (8) | 4 (10) |
| Adverse eventc | 1 (33) | 1 (25) |
| Otherc | 2 (67) | 3 (75) |
| Length of delay in definitive surgery | ||
| Median (IQR), weeks | 1.1 (0.1-2.6) | 1.2 (0.4-2.4) |
| ≤2 weeks, n (%)c | 2 (67) | 3 (75) |
| >2-4 weeks, n (%)c | 1 (33) | 1 (25) |
| Median duration of definitive surgery (IQR), minutes | 156.5 (123.5-201.0) | 158.0 (115.0-238.0) |
| Surgical approach, n (%)d | ||
| Minimally invasive | 11 (31) | 10 (24) |
| Thoracotomy | 23 (64) | 20 (49) |
| Minimally invasive to thoracotomy | 2 (6) | 11 (27) |
| Extent of resection, n (%)d,e | ||
| Lobectomy | 21 (58) | 20 (49) |
| Sleeve lobectomy | 2 (6) | 5 (12) |
| Bilobectomy | 0 | 1 (2) |
| Pneumonectomy | 12 (33) | 12 (29) |
| Other | 6 (17) | 6 (15) |
| Completeness of resection, n (%)d | ||
| R0 | 35 (97) | 38 (93) |
| R1 | 0 | 3 (7) |
| R2 | 0 | 0 |
| RX | 1 (3) | 0 |
| Median length of hospital stay following definitive surgery (IQR), days | 11.5 (9.0-15.0) | 11.0 (9.0-15.0) |
Percentages may not total 100% due to rounding.
IQR, interquartile range; R0, no residual tumor; R1, microscopic residual tumor; R2, macroscopic residual tumor; RX, unknown residual tumor.
a
The surgical status of one patient was not reported.
b
Denominator based on patients with cancelled surgery.
c
Denominator based on patients with delayed surgery.
d
Denominator based on patients who underwent surgery.
e
Patients may have undergone one or more types of surgery.